Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
people with cardiovascular disease, in this paper
Already taking Statin use, or nottheir own situation, not assigned
on Statin use
not on use
Statin use went with lower major heart events−13%
Statin use went with fewer overall deaths−16%
Statin use went with lower hepatotoxicity−19%
correlation, not a testthe abstract, start to end
… events [Relative risk (RR): 0.87, 95% confidence interval (CI): 0.67-0.96, moderate certainty] and overall mortality (RR: 0.84, 95% CI: 0.74-0.94, low …
… with a lower risk of hepatotoxicity (RR: 0.81, 95% CI: 0.70-0.93, moderate certainty), but with a greater risk of rhabdomyolysis (RR: 1.37, 95% CI: 1.10-1.70, low certainty) and cataract (RR: 1.22, 95% CI: 1.14-1.31, moderate …
← favours treatmentfavours comparator →
could be chanceMajor adverse cardiovascular eventsStatin use vs no use
RR 0.870.67–0.96
Overall mortalityStatin use vs no use
RR 0.840.74–0.94
HepatotoxicityStatin use vs no use
RR 0.810.70–0.93
RhabdomyolysisStatin use vs no use
RR 1.371.10–1.70
CataractStatin use vs no use
RR 1.221.14–1.31
StatinsCardiovascular eventsAll-cause mortalityAdverse events & safety
1 / 4